FibroBiologics Secures U.S. Patent Allowance for 3D Spheroid Fibroblast Wound Therapy Covering CYWC628 Program

A USPTO Notice of Allowance granted to FibroBiologics, Inc. for U.S. Patent Application No. 18/184,726 draws a direct IP boundary around the 3D spheroid fibroblast manufacturing and administration methods underpinning its active clinical program, a development with clear implications for CDMOs and allogeneic cell therapy developers mapping their own scale-up strategies.

The allowed application contains 19 claims directed to methods of topically administering compositions comprising three-dimensional spheroid fibroblasts, with or without fibroblast-derived materials such as exosomes and extracellular vesicles, into or adjacent to wound sites. Covered indications include chronic wounds in patients with diabetes, cancer, or compromised immune status, as well as acute wound types including cuts, abrasions, bedsores, and burns. The USPTO examiner specifically noted that the combination of 3D spheroid fibroblasts with fibroblast-derived materials is not taught by prior art, a distinction that anchors the claim set's defensive value.

The claims map directly onto CYWC628, FibroBiologics' investigational allogeneic fibroblast-spheroid therapy currently in a Phase 1/2 clinical trial in patients with diabetic foot ulcers. That patient population, individuals with diabetes presenting chronic, difficult-to-treat wounds, falls explicitly within the allowed claim language, tightening the alignment between IP coverage and clinical execution. For cell therapy developers and their manufacturing partners, the notice signals that method-of-treatment claims tied to spheroid production geometry and fibroblast-derived material combinations are now patentable territory subject to enforcement.

For QA directors and process development leads at CDMOs working in allogeneic cell therapy, the relevance is sharpest around 3D spheroid production workflows. As FibroBiologics' portfolio grows beyond 270 issued and pending patents across wound healing, multiple sclerosis, disc degeneration, and oncology, manufacturing partners will need to assess freedom-to-operate positions against claim sets that now explicitly cover spheroid formation methods and combination compositions. Process validation strategies for allogeneic cell therapies involving extracellular vesicle co-administration may warrant early IP review alongside 21 CFR Part 211 and ICH Q10 quality system documentation.

The formal patent grant, which follows the Notice of Allowance upon payment of issue fees, will set the enforceable priority date against which competing allogeneic wound-healing programs and their CDMOs will need to position their own IP and manufacturing process disclosures.

Source: FibroBiologics, Inc. via GlobeNewswire, June 22, 2026.